875155-22-9

Upstream product

• 288615-43-0 N-(2-methyl-5-trifluoromethyl-phenyl)-acetamide 
• 25449-96-1 3-amino-4-methylbenzotrifluoride 
• 875155-19-4 2-amino-5-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-18-3 2-acetylamino-5-nitro-4-trifluoromethyl-benzoic acid 
• 288615-44-1 2-Methyl-4-nitro-5-trifluoromethylacetanilide 
• 288615-45-2 2-amino-5-nitro-4-trifluoromethyl-benzoic acid 
• 875155-20-7 2-acetylamino-5-nitro-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-21-8 2-acetylamino-5-amino-4-trifluoromethyl-benzoic acid methyl ester 
• 628-36-4 diformylhydrazine 

Downstream Products

• 875155-23-0 2-acetylamino-5-[1,2,4]triazol-4-yl-4-trifluoromethyl-benzoic acid methyl ester 
• 875155-24-1 2-amino-5-[1,2,4]triazol-4-yl-4-trifluoromethyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists

A new set of quinazolinedione sulfonamide derivatives as competitive AMPA receptor antagonist with improved properties compared to 1 is disclosed. By modulating physico-chemical properties, compound 29 was identified with a low ED50 of 5.5 mg/kg in an animal model of anticonvulsant activity after oral dosage.

QUINAZOLINE DERIVATIVES

The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula (I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.